Align Technology Q4 Revenue Beats Estimates

Overview

• Medical device firm's Q4 revenue grew 5.3% yr/yr, beating analyst expectations

• Adjusted EPS for Q4 beat analyst expectations

• Company repurchased 0.7 mln shares, completing $200 mln buyback plan

Outlook

• Align expects Q1'26 worldwide revenue between $1,010M and $1,030M, up 3% to 5% year-over-year

• Align expects 2026 worldwide revenue growth of 3% to 4% year-over-year

• Align expects 2026 Clear Aligner volume growth to be up mid-single digits year-over-year

Result Drivers

• CLEAR ALIGNER VOLUME - Q4 volume reached a record 676.9 thousand cases, driven by growth in EMEA, Latin America, and Asia Pacific, with stability in North America

• SYSTEMS AND SERVICES GROWTH - Q4 revenues increased 10.3% sequentially, driven by iTero Lumina scanner sales

• FOREIGN EXCHANGE IMPACT - Q4 revenues were unfavorably impacted by foreign exchange sequentially but favorably year-over-year

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Align Technology Inc is $180.50, about 14.9% above its February 3 closing price of $157.05

• The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 13 three months ago

Press Release: ID:nBw4s7XQya

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)